Heart failure in patients with chronic kidney disease: a systematic integrative review

Liviu Segall, Ionut Nistor, Adrian Covic, Liviu Segall, Ionut Nistor, Adrian Covic

Abstract

Introduction: Heart failure (HF) is highly prevalent in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) and is strongly associated with mortality in these patients. However, the treatment of HF in this population is largely unclear.

Study design: We conducted a systematic integrative review of the literature to assess the current evidence of HF treatment in CKD patients, searching electronic databases in April 2014. Synthesis used narrative methods.

Setting and population: We focused on adults with a primary diagnosis of CKD and HF.

Selection criteria for studies: We included studies of any design, quantitative or qualitative.

Interventions: HF treatment was defined as any formal means taken to improve the symptoms of HF and/or the heart structure and function abnormalities.

Outcomes: Measures of all kinds were considered of interest.

Results: Of 1,439 results returned by database searches, 79 articles met inclusion criteria. A further 23 relevant articles were identified by hand searching.

Conclusions: Control of fluid overload, the use of beta-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and optimization of dialysis appear to be the most important methods to treat HF in CKD and ESRD patients. Aldosterone antagonists and digitalis glycosides may additionally be considered; however, their use is associated with significant risks. The role of anemia correction, control of CKD-mineral and bone disorder, and cardiac resynchronization therapy are also discussed.

Figures

Figure 1
Figure 1
Inclusion and exclusion flow diagram.
Box 1
Box 1
Treatment of HF in patients with CKD: key messages.

References

    1. U.S. Renal Data System (USRDS) Chronic kidney disease in the adult NHANES population. USRDS Annual Report Data. 2009 .
    1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. The American Journal of Kidney Diseases. 1998;32(5, supplement 3):S112–S119.
    1. Johnson DW, Craven A, Isbel NM. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodialysis International. 2007;11(1):1–14.
    1. Bagshaw SM, Cruz DN, Aspromonte N, et al. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI consensus conference. Nephrology Dialysis Transplantation. 2010;25(5):1406–1416.
    1. Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. Journal of the American Society of Nephrology. 2007;18(4):1307–1315.
    1. Soucie JM, McClellan WM. Early death in dialysis patients: risk factors and impact on incidence and mortality rates. Journal of the American Society of Nephrology. 1996;7(10):2169–2175.
    1. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney International. 1995;47(3):884–890.
    1. Wang AY, Wang M, Lam CW, Chan IH, Lui S, Sanderson JE. Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis. Clinical Journal of the American Society of Nephrology. 2011;6(4):805–812.
    1. Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC. Heart failure as a cause for hospitalization in chronic dialysis patients. The American Journal of Kidney Diseases. 2003;41(6):1267–1277.
    1. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney International. 1995;47(1):186–192.
    1. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clinical Journal of the American Society of Nephrology. 2009;4(1):S79–S91.
    1. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO) Kidney International. 2011;80(6):572–586.
    1. Cerasola G, Nardi E, Palermo A, Mulè G, Cottone S. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. Journal of Nephrology. 2011;24(1):1–10.
    1. Zoccali C, Benedetto FA, Tripepi G, Mallamaci F. Cardiac consequences of hypertension in hemodialysis patients. Seminars in Dialysis. 2004;17(4):299–303.
    1. López B, González A, Hermida N, Laviades C, Díez J. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney International. 2008;74(111):S19–S23.
    1. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. Journal of the American Society of Nephrology. 1998;9(6):1018–1022.
    1. Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney International. 2009;75(8):771–773.
    1. Gross M, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia—beyond coronary heart disease. Seminars in Dialysis. 2008;21(4):308–318.
    1. Ritz E, Wanner C. The challenge of sudden death in dialysis patients. Clinical Journal of the American Society of Nephrology. 2008;3(3):920–929.
    1. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. Journal of the American Society of Nephrology. 2001;12(5):1079–1084.
    1. Nardi E, Palermo A, Mulè G, Cusimano P, Cottone S, Cerasola G. Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. Journal of Hypertension. 2009;27(3):633–641.
    1. Marchais SJ, Metivier F, Guerin AP, London GM. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrology Dialysis Transplantation. 1999;14(9):2178–2183.
    1. Strózecki P, Adamowicz A, Nartowicz E, Odrow̧z-Sypniewska G, Włodarczyk Z, Manitius J. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Renal Failure. 2001;23(1):115–126.
    1. Chue CD, Edwards NC, Moody WE, Steeds RP, Townend JN, Ferro CJ. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart. 2012;98(3):219–224.
    1. Galetta F, Cupisti A, Franzoni F, et al. Left ventricular function and calcium phosphate plasma levels in uraemic patients. Journal of Internal Medicine. 2005;258(4):378–384.
    1. Raizada V, Hillerson D, Amaram JS, Skipper B. Angiotensin II-mediated left ventricular abnormalities in chronic kidney disease. Journal of Investigative Medicine. 2012;60(5):785–791.
    1. Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. The American Journal of Nephrology. 2007;27(2):159–163.
    1. Grassi G, Seravalle G, Ghiadoni L, et al. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clinical Journal of the American Society of Nephrology. 2011;6(11):2620–2627.
    1. National Institute of Clinical Excellence Chronic Heart Failure (NICE) National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London, UK: Royal College of Physicians; 2003. .
    1. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal. 2008;29(19):2388–2442.
    1. Wang AY, Sanderson JE. Current perspectives on diagnosis of heart failure in long-term dialysis patients. The American Journal of Kidney Diseases. 2011;57(2):308–319.
    1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the Aamerican College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–e479.
    1. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. Journal of the American College of Cardiology. 1999;33(7):1948–1955.
    1. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108(8):977–982.
    1. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal. 2007;28(20):2539–2550.
    1. Pecoits-Filho R, Barberato SH. Echocardiography in chronic kidney disease: diagnostic and prognostic implications. Nephron—Clinical Practice. 2010;114(4):c242–c247.
    1. National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. The American Journal of Kidney Diseases. 2005;45(4, supplement 3):S1–S153.
    1. Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney International. 2004;65(4):1492–1498.
    1. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. Journal of the American Society of Nephrology. 2000;11(5):912–916.
    1. Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing β-blocker therapy. Circulation. 2003;108(16):1945–1953.
    1. Wizemann V, Schilling M. Dilemma of assessing volume state—the use and the limitations of a clinical score. Nephrology Dialysis Transplantation. 1995;10(11):2114–2117.
    1. Charra B. Fluid balance, dry weight, and blood pressure in dialysis. Hemodialysis International. 2007;11(1):21–31.
    1. Katzarski KS, Nisell J, Randmaa I, Danielsson A, Freyschuss U, Bergstrom J. A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. The American Journal of Kidney Diseases. 1997;30(4):459–465.
    1. Chang ST, Chen CL, Chen CC, Lin FC, Wu D. Enhancement of quality of life with adjustment of dry weight by echocardiographic measurement of inferior vena cava diameter in patients undergoing chronic hemodialysis. Nephron—Clinical Practice. 2004;97(3):c90–c97.
    1. Santoro A, Mancini E, Basile C, et al. Blood volume controlled hemodialysis in hypotension-prone patients: a randomized, multicenter controlled trial. Kidney International. 2002;62(3):1034–1045.
    1. Sinha AD, Light RP, Agarwal R. Relative plasma volume monitoring during hemodialysis aids the assessment of dry weight. Hypertension. 2010;55(2):305–311.
    1. Dasselaar JJ, Huisman RM, de Jong PE, Franssen CFM. Measurement of relative blood volume changes during haemodialysis: merits and limitations. Nephrology Dialysis Transplantation. 2005;20(10):2043–2049.
    1. Agarwal R, Kelley K, Light RP. Diagnostic utility of blood volume monitoring in hemodialysis patients. The American Journal of Kidney Diseases. 2008;51(2):242–254.
    1. Wabel P, Chamney P, Moissl U, Jirka T. Importance of whole-body bioimpedance spectroscopy for the management of fluid balance. Blood Purification. 2009;27(1):75–80.
    1. Wizemann V, Wabel P, Chamney P, et al. The mortality risk of overhydration in haemodialysis patients. Nephrology Dialysis Transplantation. 2009;24(5):1574–1579.
    1. MacHek P, Jirka T, Moissl U, Chamney P, Wabel P. Guided optimization of fluid status in haemodialysis patients. Nephrology Dialysis Transplantation. 2010;25(2):538–544.
    1. Mallamaci F, Benedetto FA, Tripepi R, et al. Detection of pulmonary congestion by chest ultrasound in dialysis patients. JACC: Cardiovascular Imaging. 2010;3(6):586–594.
    1. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90(1):195–203.
    1. Hosoda K, Nakao K, Mukoyama M, et al. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension. 1991;17(6, part 2):1152–1155.
    1. Yamamoto K, Burnett JC, Jr., Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28(6):988–994.
    1. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. The New England Journal of Medicine. 2002;347(3):161–167.
    1. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clinical Endocrinology. 1997;47(3):287–296.
    1. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technology Assessment. 2009;13(32):1–207.
    1. Kelder JC, Cowie MR, McDonagh TA, et al. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart. 2011;97(12):959–963.
    1. Balion C, Santaguida PL, Hill S, et al. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. Evidence Report/Technology Assessment. 2006;(142):1–147.
    1. Januzzi JL., Jr. The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Archives of Cardiovascular Diseases. 2012;105(1):40–50.
    1. Codognotto M, Piccoli A, Zaninotto M, et al. Renal dysfunction is a confounder for plasma natriuretic peptides in detecting heart dysfunction in uremic and idiopathic dilated cardiomyopathies. Clinical Chemistry. 2007;53(12):2097–2104.
    1. Takami Y, Horio T, Iwashima Y, et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. The American Journal of Kidney Diseases. 2004;44(3):420–428.
    1. Apple FS, Murakami MAM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clinical Chemistry. 2004;50(12):2279–2285.
    1. Wang AY, Lam CW, Yu C, et al. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. Journal of the American Society of Nephrology. 2007;18(1):321–330.
    1. Mallamaci F, Zoccali C, Tripepi G, et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney International. 2001;59(4):1559–1566.
    1. Tripepi G, Mattace-Raso F, Mallamaci F, et al. Biomarkers of left atrial volume: a longitudinal study in patients with end stage renal disease. Hypertension. 2009;54(4):818–824.
    1. Wang AY. Clinical utility of natriuretic peptides in dialysis patients. Seminars in Dialysis. 2012;25(3):326–333.
    1. Wang AY, Sanderson JE. Treatment of heart failure in long-term dialysis patients: a reappraisal. The American Journal of Kidney Diseases. 2011;57(5):760–772.
    1. Ritz E, Dikow R, Adamzcak M, Zeier M. Congestive heart failure due to systolic dysfunction: the cinderella of cardiovascular management in dialysis patients. Seminars in Dialysis. 2002;15(3):135–140.
    1. Özkahya M, Ok E, Cirit M, et al. Regression of left ventricular hypertrophy in haemodialysis patient by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrology Dialysis Transplantation. 1998;13(6):1489–1493.
    1. Gunal AI, Karaca I, Aygen B, Yavuzkir M, Dogukan A, Celiker H. Strict fluid volume control and left ventricular hypertrophy in hypertensive patients on chronic haemodialysis: a cross-sectional study. Journal of International Medical Research. 2004;32(1):70–77.
    1. Aslam F, Haque A, Haque J, Joseph J. Heart failure in subjects with chronic kidney disease: best management practices. World Journal of Cardiology. 2010;2(5):112–117.
    1. Abdo AS, Basu A, Geraci SA. Managing chronic heart failure patient in chronic kidney disease. The American Journal of Medicine. 2011;124(1):26–28.
    1. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne A. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107(2):294–299.
    1. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. Journal of the American College of Cardiology. 2001;37(7):1775–1780.
    1. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. Journal of the American College of Cardiology. 2000;35(7):1737–1744.
    1. van der Meer P, Groenveld HF, Januzzi JL, Jr., van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart. 2009;95(16):1309–1314.
    1. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. The American Journal of Kidney Diseases. 1999;34(1):125–134.
    1. Martinez-Vea A, Marcas L, Bardají A, et al. Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease. Clinical Nephrology. 2012;77(3):171–181.
    1. Schmid H, Schiffl H, Lederer SR. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient. Current Opinion in Nephrology and Hypertension. 2011;20(5):465–470.
    1. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney International. 2000;58(3):1325–1335.
    1. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. The New England Journal of Medicine. 1998;339(9):584–590.
    1. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The New England Journal of Medicine. 2006;355(20):2071–2084.
    1. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. The New England Journal of Medicine. 2006;355(20):2085–2098.
    1. Pfeffer MA, Burdmann EA, Chen C, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. The New England Journal of Medicine. 2009;361(21):2019–2032.
    1. Timmer SAJ, de Boer K, Knaapen P, Götte MJW, van Rossum AC. The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis? Journal of Cardiac Failure. 2009;15(4):353–361.
    1. Locatelli F, Aljama P, Canaud B, et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with aranesp therapy (TREAT) study. Nephrology Dialysis Transplantation. 2010;25(9):2846–2850.
    1. Kazory A, Ross EA. Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. Circulation. 2008;117(7):975–983.
    1. Achinger SG, Ayus JC. Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? Journal of the American Society of Nephrology. 2006;17(12, supplement 3):S255–S261.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney International Supplements. 2009;76:S1–S2.
    1. Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database of Systematic Reviews. 2011;(2)CD006023
    1. Silver J, Rodriguez M, Slatopolsky E. FGF23 and PTH—double agents at the heart of CKD. Nephrology Dialysis Transplantation. 2012;27(5):1715–1720.
    1. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. Journal of Clinical Investigation. 2011;121(11):4393–4408.
    1. Fujii H, Kim JI, Abe T, Umezu M, Fukagawa M. Relationship between parathyroid hormone and cardiac abnormalities in chronic dialysis patients. Internal Medicine. 2007;46(18):1507–1512.
    1. Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. Journal of Clinical Investigation. 1987;79(6):1706–1712.
    1. Cozzolino M, Ronco C. The impact of paricalcitol on left ventricular hypertrophy. Contributions to Nephrology. 2011;171:161–165.
    1. Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. Journal of Clinical Investigation. 1996;97(7):1577–1588.
    1. Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(43):16810–16815.
    1. Wang AY, Lam CW, Sanderson JE, et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. The American Journal of Clinical Nutrition. 2008;87(6):1631–1638.
    1. Park CW, Oh YS, Shin YS, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. The American Journal of Kidney Diseases. 1999;33(1):73–81.
    1. Ivarsen P, Povlsen JV, Christensen KL. Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: a pilot study. Scandinavian Journal of Urology. 2012;46(5):381–388.
    1. Bucharles S, Barberato SH, Stinghen AEM, et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. Journal of Renal Nutrition. 2012;22(2):284–291.
    1. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. The Journal of the American Medical Association. 2012;307(7):674–684.
    1. Ligtenberg G. Regulation of blood pressure in chronic renal failure: determinants of hypertension and dialysis-related hypotension. Netherlands Journal of Medicine. 1999;55(1):13–18.
    1. Bernardi D, Bernini L, Cini G, Ghione S, Bonechi I. Asymmetric septal hypertrophy and sympathetic overactivity in normotensive hemodialyzed patients. The American Heart Journal. 1985;109(3, part 1):539–545.
    1. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105(11):1354–1359.
    1. Badve SV, Roberts MA, Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. Journal of the American College of Cardiology. 2011;58(11):1152–1161.
    1. Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. Journal of the American College of Cardiology. 2004;44(8):1587–1592.
    1. Shlipak MG, Browner WS, Noguchi H, Massie B, Frances CD, McClellan M. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. The American Journal of Medicine. 2001;110(6):425–433.
    1. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL. β-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Archives of Internal Medicine. 2004;164(22):2465–2471.
    1. Ghali JK, Wikstrand J, van Veldhuisen DJ, et al. The influence of renal function on clinical outcome and response to β-blockade in systolic heart failure: insights from metoprolol CR/XL randomized intervention trial in chronic HF (MERIT-HF) Journal of Cardiac Failure. 2009;15(4):310–318.
    1. Castagno D, Jhund PS, McMurray JJV, et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. European Journal of Heart Failure. 2010;12(6):607–616.
    1. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure. 2009;11(9):872–880.
    1. Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients—beneficial effects of carvedilol: a double-blind, placebo-controlled trial. Journal of the American College of Cardiology. 2001;37(2):407–411.
    1. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. Journal of the American College of Cardiology. 2003;41(9):1438–1444.
    1. Ascenção R, Fortuna P, Reis I, Carneiro AV. Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: a review. III. Angiotensin-converting enzyme inhibitors. Revista Portuguesa de Cardiologia. 2008;27(9):1169–1187.
    1. Acquarone N, Castello C, Antonucci G, Lione S, Bellotti P. Pharmacologic therapy in patients with chronic heart failure and chronic kidney disease: a complex issue. Journal of Cardiovascular Medicine. 2009;10(1):13–21.
    1. Amann K, Tyralla K, Gross M, et al. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney International. 2003;63(5):1708–1713.
    1. Amann K, Gassmann P, Buzello M, et al. Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats. Kidney International. 2000;58(1):153–161.
    1. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109(8):1004–1009.
    1. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Archives of Internal Medicine. 2000;160(17):2645–2650.
    1. Ahmed A, Love TE, Sui X, Rich MW. Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. Journal of Cardiac Failure. 2006;12(7):499–506.
    1. Tokmakova MP, Skali H, Kenchaiah S, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) study. Circulation. 2004;110(24):3667–3673.
    1. Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD treatment trial. International Journal of Cardiology. 2013;167(1):151–156.
    1. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: comparative effects of ACE inhibition and calcium channel blockade. Circulation. 1994;90(6):2786–2796.
    1. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. The American Journal of Kidney Diseases. 1997;30(5):659–664.
    1. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103(7):987–992.
    1. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney International. 2006;70(7):1318–1324.
    1. Chang TI, Shilane D, Brunelli SM, Cheung AK, Chertow GM, Winkelmayer WC. Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. The American Heart Journal. 2011;162(2):324–330.
    1. Berger AK, Duval S, Manske C, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. The American Heart Journal. 2007;153(6):1064–1073.
    1. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. The Lancet. 2000;355(9215):1575–1581.
    1. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Archives of Internal Medicine. 2000;160(5):685–693.
    1. Khan NA, Ma I, Thompson CR, et al. Kidney function and mortality among patients with left ventricular systolic dysfunction. Journal of the American Society of Nephrology. 2006;17(1):244–253.
    1. Gradman AH, Papademetriou V. Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. The American Heart Journal. 2009;157(6, supplement):S17–S23.
    1. de Denus S, Tardif J, White M, et al. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction. A retrospective analysis of the studies of left ventricular dysfunction (SOLVD) trials. The American Heart Journal. 2006;152(4):705–712.
    1. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. The New England Journal of Medicine. 2004;351(6):585–622.
    1. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. The Lancet. 2003;362(9386):772–776.
    1. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. The New England Journal of Medicine. 2001;345(23):1667–1675.
    1. Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. Journal of the American College of Cardiology. 2002;40(5):970–975.
    1. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. The New England Journal of Medicine. 2003;349(20):1893–1906.
    1. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. The Lancet. 2003;362(9386):777–781.
    1. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England Journal of Medicine. 2001;345(12):861–869.
    1. Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011;123(10):1098–1107.
    1. Ahmed A, Fonarow GC, Zhang Y, et al. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. The American Journal of Medicine. 2012;125(4):399–410.
    1. Cice G, Di Benedetto A, D’Isa S, et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial. Journal of the American College of Cardiology. 2010;56(21):1701–1708.
    1. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. Journal of Endocrinology. 1981;91(3):457–465.
    1. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ace inhibitors. Journal of Clinical Pharmacology. 1993;33(1):40–45.
    1. Weber KT. Aldosterone in congestive heart failure. The New England Journal of Medicine. 2001;345(23):1689–1697.
    1. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nature Reviews Nephrology. 2010;6(5):261–273.
    1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. The New England Journal of Medicine. 1999;341(10):709–717.
    1. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine. 2003;348(14):1309–1321.
    1. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. Journal of the American College of Cardiology. 2005;46(3):425–431.
    1. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease. A randomized controlled trial. Journal of the American College of Cardiology. 2009;54(6):505–512.
    1. Taheri S, Mortazavi M, Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases and Transplantation. 2009;20(3):392–397.
    1. Taheri S, Mortazavi M, Pourmoghadas A, Seyrafian S, Alipour Z, Karimi S. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi Journal of Kidney Diseases and Transplantation. 2012;23(3):507–512.
    1. Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? Clinical Cardiology. 2010;33(10):604–608.
    1. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. The New England Journal of Medicine. 1997;336(8):525–533.
    1. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. Journal of the American Society of Nephrology. 2004;15(8):2195–2203.
    1. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. European Heart Journal. 2006;27(2):178–186.
    1. Thiemann DR. Digitalis and hemodialysis is a bad combination. Journal of the American Society of Nephrology. 2010;21(9):1418–1420.
    1. Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. Journal of the American Society of Nephrology. 2010;21(9):1550–1559.
    1. Bleeker GB, Bax JJ, Steendijk P, Schalij MJ, van der Wall EE. Left ventricular dyssynchrony in patients with heart failure: pathophysiology, diagnosis and treatment. Nature Clinical Practice Cardiovascular Medicine. 2006;3(4):213–219.
    1. Penicka M, Bartunek J, Lang O, et al. Severe left ventricular dyssynchrony is associated with poor prognosis in patients with moderate systolic heart failure undergoing coronary artery bypass grafting. Journal of the American College of Cardiology. 2007;50(14):1315–1323.
    1. Shin SH, Hung CL, Uno H, et al. Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both. Circulation. 2010;121(9):1096–1103.
    1. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. The Journal of the American Medical Association. 2007;297(22):2502–2514.
    1. Cannizzaro LA, Piccini JP, Patel UD, Hernandez AF. Device therapy in heart failure patients with chronic kidney disease. Journal of the American College of Cardiology. 2011;58(9):889–896.
    1. Boerrigter G, Costello-Boerrigter LC, Abraham WT, et al. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. Journal of Cardiac Failure. 2008;14(7):539–546.
    1. Asif A, Salman LH, Lopera GG, Carrillo RG. The dilemma of transvenous cardiac rhythm devices in hemodialysis patients: time to consider the epicardial approach. Kidney International. 2011;79(12):1267–1269.
    1. Ganda A, Weiner SD, Chudasama NL, et al. Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction. Clinical Nephrology. 2012;77(5):366–375.
    1. Libetta C, Sepe V, Zucchi M, et al. Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrology Dialysis Transplantation. 2007;22(7):2013–2019.
    1. McIntyre CW. Haemodialysis-induced myocardial stunning in chronic kidney disease—a new aspect of cardiovascular disease. Blood Purification. 2010;29(2):105–110.
    1. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clinical Journal of the American Society of Nephrology. 2009;4(12):1925–1931.
    1. Selby NM, Lambie SH, Camici PG, Baker CS, McIntyre CW. Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. The American Journal of Kidney Diseases. 2006;47(5):830–841.
    1. Selby NM, Burton JO, Chesterton LJ, McIntyre CW. Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clinical Journal of the American Society of Nephrology. 2006;1(6):1216–1225.
    1. MacRae JM, Pandeya S, Humen DP, Krivitski N, Lindsay RM. Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. The American Journal of Kidney Diseases. 2004;43(5):e17–e22.
    1. Charra B, Bergstrom J, Scribner BH. Blood pressure control in dialysis patients: importance of the lag phenomenon. The American Journal of Kidney Diseases. 1998;32(5):720–724.
    1. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. The Journal of the American Medical Association. 2007;298(11):1291–1299.
    1. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. Journal of the American Society of Nephrology. 2005;16(9):2778–2788.
    1. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension. 2003;42(5):925–931.
    1. Chan C, Floras JS, Miller JA, Pierratos A. Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrology Dialysis Transplantation. 2002;17(8):1518–1521.
    1. Chan CT, Greene T, Chertow GM, et al. Determinants of left ventricular mass in patients on hemodialysis: frequent hemodialysis network (FHN) trials. Circulation: Cardiovascular Imaging. 2012;5(2):251–261.
    1. Hamburger RJ, Christ PG, Morris PA, Luft FC. Hypertension in dialysis patients: does CAPD provide an advantage? Advances in Peritoneal Dialysis. 1989;5:91–96.
    1. Lameire N. Cardiovascular risk factors and blood pressure control in continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International. 1993;13(supplement 2):S394–S395.
    1. Dasgupta I, Burden R. Blood pressure control before and after starting dialysis. Nephron—Clinical Practice. 2005;99(3):c86–c91.
    1. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrology Dialysis Transplantation. 2001;16(11):2207–2213.
    1. Ateş K, Nergizoğlu G, Keven K, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney International. 2001;60(2):767–776.
    1. Enia G, Mallamaci F, Benedetto FA, et al. Long-term CAPD patients are volume expanded and display more severe left venticular hypertrophy than haemodialysis patients. Nephrology Dialysis Transplantation. 2001;16(7):1459–1464.
    1. Konings CJ, Kooman JP, Schonck M, et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrology Dialysis Transplantation. 2003;18(4):797–803.
    1. Margetts PJ, Churchill DN. Acquired ultrafiltration dysfunction in peritoneal dialysis patients. Journal of the American Society of Nephrology. 2002;13(11):2787–2794.
    1. Aşci G, Özkahya M, Duman S, Toz H, Erten S, Ok E. Volume control associated with better cardiac function in long-term peritoneal dialysis patients. Peritoneal Dialysis International. 2006;26(1):85–88.
    1. Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney International. 2003;63(4):1556–1563.
    1. Stack AG, Molony DA, Rahman NS, Dosekun A, Murthy B. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney International. 2003;64(3):1071–1079.
    1. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney International. 2004;66(6):2389–2401.
    1. McMurray JJV, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure. 2008;1(1):17–24.
    1. Sever PS, Gradman AH, Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. Journal of the Renin-Angiotensin-Aldosterone System. 2009;10(2):65–76.
    1. Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure. 2012;14(6):668–675.
    1. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107(25):3133–3140.
    1. Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL) Circulation. 2004;109(13):1594–1602.
    1. Kelland NF, Webb DJ. Clinical trials of endothelin antagonists in heart failure: a question of dose? Experimental Biology and Medicine. 2006;231(6):696–699.
    1. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE) Circulation. 2002;106(8):920–926.
    1. Reilly T, Schork MR. Vasopressin antagonists: pharmacotherapy for the treatment of heart failure. Annals of Pharmacotherapy. 2010;44(4):680–687.
    1. Sata Y, Krum H. The future of pharmacological therapy for heart failure. Circulation Journal. 2010;74(5):809–817.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit